|1.||Hansen, Henrik H: 4 articles (09/2013 - 06/2010)|
|2.||Mikkelsen, Jens D: 4 articles (09/2013 - 01/2007)|
|3.||Astrup, Arne: 4 articles (03/2012 - 06/2008)|
|4.||Meier, Dieter H: 2 articles (03/2012 - 06/2008)|
|5.||Raben, Anne: 2 articles (03/2012 - 06/2010)|
|6.||Meier, D: 2 articles (11/2010 - 07/2010)|
|7.||Axel, Anne Marie D: 2 articles (06/2010 - 06/2010)|
|8.||Lehr, Thorsten: 2 articles (06/2010 - 07/2007)|
|9.||Schaefer, Hans Guenter: 2 articles (06/2010 - 07/2007)|
|10.||Trommeshauser, Dirk: 2 articles (06/2010 - 07/2007)|
|1.||Parkinson Disease (Parkinson's Disease)
05/01/2008 - "To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD). "
05/01/2008 - "Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study."
02/15/2007 - "The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). "
02/15/2007 - "Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease."
01/01/2008 - "Tesofensine is a centrally acting drug under clinical development for Alzheimer's disease, Parkinson's disease and obesity. "
06/25/2010 - "The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity. "
10/05/2009 - "Results from a phase II trial with Tesofensine for treatment of obesity are presented. "
10/01/2009 - "The initial positive findings suggest that tesofensine may be a well-tolerated long-term treatment for obesity, with minimal cardiovascular effects; this view appears to be shared by the FDA, which recently endorsed the phase III trial program for the agent."
09/01/2013 - "Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong and sustained effects in obesity management is not clarified. "
05/01/2013 - "These data suggests that tesofensine causes elevations in heart rate and blood pressure by increasing sympathetic activity, and that different adrenoceptor subtypes may be responsible for the anti-obesity and cardiovascular effects of tesofensine."
|3.||Body Weight (Weight, Body)
06/25/2010 - "In contrast to tesofensine, the body weight of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure. "
06/01/2010 - "DIO rats treated with tesofensine (2.0 mg/kg, s.c.) for 16 days showed significantly lower body weights than vehicle-treated DIO rats, being reflected by a marked hypophagic response. "
10/05/2009 - "[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]."
10/01/2009 - "In phase II clinical trials with tesofensine in obese individuals, dose-related reductions in body weight, body fat and waist circumference, as well as improvements in other obesity-related endocrine factors, were observed. "
10/01/2009 - "Preclinical data from diet-induced obese rats supported the hypothesis that tesofensine reduces body weight, and NeuroSearch has since pursued the development of the compound as an oral anti-obesity drug. "
|4.||Weight Loss (Weight Reduction)
12/03/2011 - "The monoaminergic re-uptake inhibitor tesofensine has also been shown to produce impressive weight loss in smaller-scale clinical studies. "
03/01/2012 - "Tesofensine (TE), an inhibitor of monoamine presynaptic reuptake, has produced twice the weight loss seen with currently marketed drugs. "
11/01/2010 - "Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs. "
06/25/2010 - "In conclusion, the robust weight loss with long-term tesofensine treatment is likely due to a combined synergistic effect of appetite suppression and increased energy expenditure."
06/25/2010 - "Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively. "
|5.||AIDS-Related Complex (ARC)
01/26/2007 - "This study was undertaken to examine the effect of sub-chronic (5 days) and chronic (14 days) administration of Tesofensine on the expression of brain derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton protein (Arc) in the rat hippocampus. "
01/26/2007 - "We find that chronic, but not sub-chronic treatment with Tesofensine increases BDNF mRNA in the CA3 region of the hippocampus (35%), and Arc mRNA in the CA1 of the hippocampus (65%). "
|4.||Brain-Derived Neurotrophic Factor (BDNF)
|8.||N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamide
|9.||8- chloro- 2,3,4,5- tetrahydro- 1- methyl- 1H- 3- benzazepine
|1.||Drug Therapy (Chemotherapy)